SG11201408101TA - Vaccination with interleukin-4 antagonists - Google Patents
Vaccination with interleukin-4 antagonistsInfo
- Publication number
- SG11201408101TA SG11201408101TA SG11201408101TA SG11201408101TA SG11201408101TA SG 11201408101T A SG11201408101T A SG 11201408101TA SG 11201408101T A SG11201408101T A SG 11201408101TA SG 11201408101T A SG11201408101T A SG 11201408101TA SG 11201408101T A SG11201408101T A SG 11201408101TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- international
- antigen
- interleukin
- australian
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 102000004388 Interleukin-4 Human genes 0.000 title abstract 2
- 108090000978 Interleukin-4 Proteins 0.000 title abstract 2
- 229940028885 interleukin-4 Drugs 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 abstract 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902345A AU2012902345A0 (en) | 2012-06-05 | Vaccination with Interleukin-4 Antagonists | |
| PCT/AU2013/000589 WO2013181696A1 (en) | 2012-06-05 | 2013-06-05 | Vaccination with interleukin-4 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408101TA true SG11201408101TA (en) | 2015-01-29 |
Family
ID=49711200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408101TA SG11201408101TA (en) | 2012-06-05 | 2013-06-05 | Vaccination with interleukin-4 antagonists |
Country Status (15)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017143270A1 (en) | 2016-02-19 | 2017-08-24 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist |
| CN113527485B (zh) * | 2020-04-17 | 2024-11-15 | 湖南麦济生物技术股份有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| JP3282188B2 (ja) | 1991-06-27 | 2002-05-13 | 日本電気株式会社 | 半導体メモリ装置 |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| EP1512693B1 (en) | 1993-03-31 | 2008-11-19 | Nippon Zeon Co., Ltd. | Novel polypeptide, DNA coding for said polypeptide, recombinant vector containing said DNA, recombinant virus prepared using said vector, and use thereof |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| CA2501743C (en) | 1994-01-21 | 2008-11-18 | Powderject Vaccines, Inc. | Gas driven gene delivery instrument |
| GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
| US6265387B1 (en) | 1995-10-11 | 2001-07-24 | Mirus, Inc. | Process of delivering naked DNA into a hepatocyte via bile duct |
| US6465634B1 (en) | 1996-04-05 | 2002-10-15 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| EP0944717A1 (fr) | 1996-07-01 | 1999-09-29 | Aventis Pharma S.A. | Procede de production d'adenovirus recombinants |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| JP2001526900A (ja) | 1997-12-23 | 2001-12-25 | イントロヘーネ ベスローテン フェンノートシャップ | 標的細胞の染色体ｄｎａへの外来遺伝子情報の組み込みに有用な、アデノ随伴ウイルスおよびアデノウイルスのキメラ組換えウイルス |
| US7922709B2 (en) | 1998-07-13 | 2011-04-12 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
| US6972013B1 (en) | 1998-07-13 | 2005-12-06 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
| US7608273B2 (en) | 1998-08-12 | 2009-10-27 | University Of Western Ontario | Recombinant lentivirus encoding modified GP 120 signal sequences |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| JP4693244B2 (ja) | 1999-03-18 | 2011-06-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法 |
| DE60035676T2 (de) | 1999-04-29 | 2008-04-30 | Cell Genesys, Inc., South San Francisco | Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| WO2001083797A2 (en) | 2000-04-28 | 2001-11-08 | Avigen, Inc. | Polynucleotides for use in recombinant adeno-associated virus virion production |
| CN1653183B (zh) | 2002-05-16 | 2012-07-25 | 巴法里安诺迪克有限公司 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| AU2003263653A1 (en) | 2002-09-27 | 2004-04-19 | Daewoong Co., Ltd. | A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus |
| US8287879B2 (en) * | 2003-10-16 | 2012-10-16 | The Regents Of The University Of California | Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use |
| WO2006012221A2 (en) | 2004-06-25 | 2006-02-02 | The Regents Of The University Of California | Target cell-specific short interfering rna and methods of use thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| US7541046B1 (en) | 2005-01-04 | 2009-06-02 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US7611690B2 (en) | 2005-01-04 | 2009-11-03 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US8048404B1 (en) | 2005-01-04 | 2011-11-01 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles for protein drug delivery |
| WO2006116182A1 (en) | 2005-04-24 | 2006-11-02 | Acambis Inc. | Recombinant flavivirus vaccines |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| MX2008008968A (es) * | 2006-01-11 | 2008-09-10 | Aerovance Inc | Metodos y composiciones para tratar asma en primates humanos y no humanos. |
| AR066240A1 (es) * | 2007-04-23 | 2009-08-05 | Wyeth Corp | Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13 |
| WO2010120511A2 (en) * | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Method of treating respiratory disorders |
| WO2011003138A1 (en) * | 2009-07-06 | 2011-01-13 | The Australian National University | Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
-
2013
- 2013-06-05 HK HK15103819.6A patent/HK1203358A1/xx unknown
- 2013-06-05 CN CN201380040156.6A patent/CN104717971A/zh active Pending
- 2013-06-05 BR BR112014030436A patent/BR112014030436A2/pt not_active IP Right Cessation
- 2013-06-05 IN IN10408DEN2014 patent/IN2014DN10408A/en unknown
- 2013-06-05 CA CA2875683A patent/CA2875683A1/en not_active Abandoned
- 2013-06-05 WO PCT/AU2013/000589 patent/WO2013181696A1/en active Application Filing
- 2013-06-05 NZ NZ702721A patent/NZ702721A/en not_active IP Right Cessation
- 2013-06-05 AU AU2013271338A patent/AU2013271338B2/en active Active
- 2013-06-05 JP JP2015515352A patent/JP2015520175A/ja active Pending
- 2013-06-05 SG SG11201408101TA patent/SG11201408101TA/en unknown
- 2013-06-05 EP EP19150395.2A patent/EP3530283A1/en not_active Withdrawn
- 2013-06-05 US US14/405,704 patent/US20150150963A1/en not_active Abandoned
- 2013-06-05 KR KR20147037109A patent/KR20150021088A/ko not_active Withdrawn
- 2013-06-05 EP EP13800233.2A patent/EP2854837A4/en not_active Withdrawn
-
2014
- 2014-12-04 IL IL236092A patent/IL236092A0/en unknown
- 2014-12-10 ZA ZA2014/09076A patent/ZA201409076B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL236092A0 (en) | 2015-01-29 |
| EP2854837A4 (en) | 2016-06-29 |
| HK1203358A1 (en) | 2015-10-30 |
| WO2013181696A1 (en) | 2013-12-12 |
| AU2013271338B2 (en) | 2018-05-24 |
| NZ702721A (en) | 2016-11-25 |
| EP3530283A1 (en) | 2019-08-28 |
| CA2875683A1 (en) | 2013-12-12 |
| ZA201409076B (en) | 2017-06-28 |
| CN104717971A (zh) | 2015-06-17 |
| KR20150021088A (ko) | 2015-02-27 |
| IN2014DN10408A (enrdf_load_stackoverflow) | 2015-08-14 |
| JP2015520175A (ja) | 2015-07-16 |
| AU2013271338A1 (en) | 2015-01-15 |
| US20150150963A1 (en) | 2015-06-04 |
| EP2854837A1 (en) | 2015-04-08 |
| BR112014030436A2 (pt) | 2017-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407200TA (en) | Liquid formulation | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201407919WA (en) | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11201407995RA (en) | Stabilized gp120 | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201909495PA (en) | Combination cancer immunotherapy with pentaaza macrocyclic ring complex | |
| SG11201407988UA (en) | Process for improved opioid synthesis | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201907207UA (en) | Pharmaceutical combinations comprising an anti-ly75 antibody | |
| SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof |